Literature DB >> 31710716

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors.

Stephen P H Alexander1, Doriano Fabbro2, Eamonn Kelly3, Alistair Mathie4, John A Peters5, Emma L Veale4, Jane F Armstrong6, Elena Faccenda6, Simon D Harding6, Adam J Pawson6, Joanna L Sharman6, Christopher Southan6, Jamie A Davies6.   

Abstract

The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.14751. Catalytic receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, ion channels, nuclear hormone receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2019, and supersedes data presented in the 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.
© 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society.

Entities:  

Year:  2019        PMID: 31710716      PMCID: PMC6844576          DOI: 10.1111/bph.14751

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  1 in total

Review 1.  Lateral signaling enhances TGF-beta response complexity.

Authors:  Stacey DaCosta Byfield; Anita B Roberts
Journal:  Trends Cell Biol       Date:  2004-03       Impact factor: 20.808

  1 in total
  80 in total

Review 1.  Interventions in the B-type natriuretic peptide signalling pathway as a means of controlling chronic itch.

Authors:  Jianghui Meng; Weiwei Chen; Jiafu Wang
Journal:  Br J Pharmacol       Date:  2020-02-12       Impact factor: 8.739

Review 2.  Human skin models: From healthy to disease-mimetic systems; characteristics and applications.

Authors:  Tânia Moniz; Sofia A Costa Lima; Salette Reis
Journal:  Br J Pharmacol       Date:  2020-08-19       Impact factor: 8.739

Review 3.  Immunoregulatory effects and therapeutic potential of vitamin D in multiple sclerosis.

Authors:  Wei Zhen Yeh; Melissa Gresle; Vilija Jokubaitis; Jim Stankovich; Anneke van der Walt; Helmut Butzkueven
Journal:  Br J Pharmacol       Date:  2020-08-05       Impact factor: 8.739

4.  Antidiabetic activity in vitro and in vivo of BDB, a selective inhibitor of protein tyrosine phosphatase 1B, from Rhodomela confervoides.

Authors:  Jiao Luo; Meiling Zheng; Bo Jiang; Chao Li; Shuju Guo; Lijun Wang; Xiangqian Li; Rilei Yu; Dayong Shi
Journal:  Br J Pharmacol       Date:  2020-08-30       Impact factor: 8.739

Review 5.  Old dog, new trick: Trivalent arsenic as an immunomodulatory drug.

Authors:  Yishan Ye; Béatrice Gaugler; Mohamad Mohty; Florent Malard
Journal:  Br J Pharmacol       Date:  2020-03-12       Impact factor: 8.739

Review 6.  Exploring microRNAs in diabetic chronic cutaneous ulcers: Regulatory mechanisms and therapeutic potential.

Authors:  Xuqiang Nie; Jiufeng Zhao; Hua Ling; Youcai Deng; Xiaohui Li; Yuqi He
Journal:  Br J Pharmacol       Date:  2020-08-13       Impact factor: 8.739

7.  Astaxanthin attenuates hepatic damage and mitochondrial dysfunction in non-alcoholic fatty liver disease by up-regulating the FGF21/PGC-1α pathway.

Authors:  Liwei Wu; Wenhui Mo; Jiao Feng; Jingjing Li; Qiang Yu; Sainan Li; Jie Zhang; Kan Chen; Jie Ji; Weiqi Dai; Jianye Wu; Xuanfu Xu; Yuqing Mao; Chuanyong Guo
Journal:  Br J Pharmacol       Date:  2020-06-27       Impact factor: 8.739

8.  The enhanced immunopharmacology of VIB4920, a novel Tn3 fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys.

Authors:  Simone M Nicholson; Kerry A Casey; Michele Gunsior; Stacey Drabic; William Iverson; Halie Cook; Stephen Scott; Terry O'Day; Subramanya Karanth; Rakesh Dixit; Patricia C Ryan
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

Review 9.  Proteolysis-targeting chimeras in drug development: A safety perspective.

Authors:  Kevin Moreau; Muireann Coen; Andrew X Zhang; Fiona Pachl; M Paola Castaldi; Goran Dahl; Helen Boyd; Clay Scott; Pete Newham
Journal:  Br J Pharmacol       Date:  2020-02-25       Impact factor: 8.739

10.  Vaccines targeting the primary amino acid sequence and conformational epitope of amyloid-β had distinct effects on neuropathology and cognitive deficits in EAE/AD mice.

Authors:  Xiao-Lin Yu; Jie Zhu; Xiang-Meng Liu; Peng-Xin Xu; Yue Zhang; Rui-Tian Liu
Journal:  Br J Pharmacol       Date:  2020-03-20       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.